MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2011.37.3472

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012

Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Ishida Takashi, Joh Tatsuro, Uike Naokuni, Yamamoto Kazuhito, Utsunomiya Atae, Yoshida Shinichiro, Saburi Yoshio, Miyamoto Toshihiro, Takemoto Shigeki, Suzushima Hitoshi, Tsukasaki Kunihiro, Nosaka Kisato, Fujiwara Hiroshi, Ishitsuka Kenji, Inagaki Hiroshi, Ogura Michinori, Akinaga Shiro, Tomonaga Masao, Tobinai Kensei, Ueda Ryuzo

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options. Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.

PATIENTS AND

METHODS

A multicenter phase II study of KW-0761 for patients with relapsed, aggressive CCR4-positive ATL was conducted to evaluate efficacy, pharmacokinetic profile, and safety. The primary end point was overall response rate, and secondary end points included progression-free and overall survival from the first dose of KW-0761. Patients received intravenous infusions of KW-0761 once per week for 8 weeks at a dose of 1.0 mg/kg.

RESULTS

Of 28 patients enrolled onto the study, 27 received at least one infusion of KW-0761. Objective responses were noted in 13 of 26 evaluable patients, including eight complete responses, with an overall response rate of 50% (95% CI, 30% to 70%). Median progression-free and overall survival were 5.2 and 13.7 months, respectively. The mean half-life period after the eighth infusion was 422 ± 147 hours (± standard deviation). The most common adverse events were infusion reactions (89%) and skin rashes (63%), which were manageable and reversible in all cases.

CONCLUSION

KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile. Further investigation of KW-0761 for treatment of ATL and other T-cell neoplasms is warranted.

Для цитирования: Ishida Takashi, Joh Tatsuro, Uike Naokuni, Yamamoto Kazuhito, Utsunomiya Atae, Yoshida Shinichiro, Saburi Yoshio, Miyamoto Toshihiro, Takemoto Shigeki, Suzushima Hitoshi, Tsukasaki Kunihiro, Nosaka Kisato, Fujiwara Hiroshi, Ishitsuka Kenji, Inagaki Hiroshi, Ogura Michinori, Akinaga Shiro, Tomonaga Masao, Tobinai Kensei, Ueda Ryuzo. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. DOI: 10.1200/jco.2011.37.3472.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.